---
schema_version: "secwatch.filing_event.v1"
accession: "0000939767-25-000074"
form_type: "8-K"
ticker: "EXEL"
cik: "0000939767"
company_name: "EXELIXIS, INC."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T22:37:45.197339+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Exelixis Q1 2025: Revenue $555.4M, GAAP EPS $0.55; raises FY2025 guidance by $100M

## Summary
- Total revenues $555.4M (up 31% YoY); Cabozantinib U.S. net product revenues $513.3M (up 36% YoY).
- GAAP diluted EPS $0.55 vs $0.12 in Q1 2024; Non-GAAP diluted EPS $0.62 vs $0.17.
- Increasing 2025 full year net product revenues and total revenues guidance by $100M.
- CABOMETYX launched in advanced NET after March FDA approval; initial reception positive.
- Pipeline milestones: zanzalintinib pivotal readouts in CRC, nccRCC expected H2 2025.

## SEC filing metadata
- accession: 0000939767-25-000074
- form_type: 8-K
- ticker: EXEL
- cik: 0000939767
- company_name: EXELIXIS, INC.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/939767/000093976725000074/0000939767-25-000074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/939767/000093976725000074/exel-20250513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000939767-25-000074
- JSON: https://secwatch.observer/filing/0000939767-25-000074.json
- Plain text: https://secwatch.observer/filing/0000939767-25-000074.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.